Chargement en cours...
Lenvatinib as first-line therapy for recurrent hepatocellular carcinoma after liver transplantation: Is the current evidence applicable to these patients?
Liver transplantation (LT) is one of the leading curative therapies for hepatocellular carcinoma (HCC). Despite recent optimization of transplant selection criteria, including alpha-feto protein, HCC recurrence after LT is still the leading cause of death in these patients. During the last decades,...
Enregistré dans:
| Publié dans: | World J Transplant |
|---|---|
| Auteurs principaux: | , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Baishideng Publishing Group Inc
2020
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7708877/ https://ncbi.nlm.nih.gov/pubmed/33312891 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5500/wjt.v10.i11.297 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|